Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 479

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 479
---
 Class A common stock, exercisable at $11.50 per share (the “Forfeited Private Placement Warrants”), acquired by the Sponsor in March 2021 in connection with the Initial Public Offering. At the Closing, the Forfeited Private Placement Warrants shall be transferred from the Sponsor to the Company for cancellation in exchange for no consideration and the Company shall retire and cancel all of the Forfeited Private Placement Warrants. NOTE 5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES As of December 31, 2023 and 2022, the accounts payable and accrued liabilities of the Company consisted of the following:

| ​                        | ​ | ​ | December 31,2023 |   |           |   | ​ | ​ | December 31,2022 |   |           |   | ​ |
|:-------------------------|:--|:--|:-----------------|:--|----------:|:--|:--|:--|:-----------------|:--|----------:|:--|:--|
| Accounts payable         | ​ | ​ | ​                | $ | 1,996,912 | ​ | ​ | ​ | ​                | $ |   594,958 | ​ | ​ |
| Accrued legal expense    | ​ | ​ | ​                | ​ |    45,400 | ​ | ​ | ​ | ​                | ​ |   826,134 | ​ | ​ |
| Accrued expenses – other | ​ | ​ | ​                | ​ |   284,606 | ​ | ​ | ​ | ​                | ​ |    68,370 | ​ | ​ |
| ​                        | ​ | ​ | ​                | $ | 2,326,918 | ​ | ​ | ​ | ​                | $ | 1,489,462 | ​ | ​ |

F-44

TABLE OF CONTENTS

### IRIS ACQUISITION CORP

### NOTES TO FINANCIAL STATEMENTS

#### NOTE 6.   RELATED PARTY TRANSACTIONS

#### Founder Shares
In December 2020, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B common stock, par value $0.0001 (the “Founder Shares”). In February 2021, the Company effected a stock dividend of 0.2 shares for each